Haemonetics (HAE) Depreciation & Amortization (CF) (2009 - 2026)

Haemonetics' Depreciation & Amortization (CF) history runs 18 years deep, the most recent figure standing at $27.3 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 3.15% year-over-year to $27.3 million in Q1 2026; TTM through Mar 2026 was $111.7 million, a 3.35% decrease from a year earlier, with the FY2026 full-year figure at $111.7 million, down 3.35% from the prior year.
• Depreciation & Amortization (CF) steadied at $27.3 million in Q1 2026 per HAE's latest filing, from $27.4 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $29.2 million in Q3 2024 and bottomed at $22.4 million in Q3 2022.
• The 5-year median for Depreciation & Amortization (CF) is $26.1 million (2022), against an average of $25.9 million.
• Across the five-year window, Depreciation & Amortization (CF) slipped 10.33% in 2022 and grew 26.96% in 2024, its largest moves.
• Year by year, Depreciation & Amortization (CF) stood at $23.6 million in 2022, then fell by 0.17% to $23.5 million in 2023, then gained by 23.35% to $29.0 million in 2024, then fell by 5.65% to $27.4 million in 2025, then retreated by 0.24% to $27.3 million in 2026.
• Per Business Quant, the three latest HAE Depreciation & Amortization (CF) figures stand at $27.3 million (Q1 2026), $27.4 million (Q4 2025), and $28.3 million (Q3 2025).